Product information and disease descriptionProduct descriptionProduct information
Dosage forms and strengths
4 evidence topics · 4 sources
Pharmaceutical form and route of administration
| Field | Quoted record |
|---|---|
| Active substance | “ifezuntirgene inilparvovec” |
| Condition | “Treatment of Huntington’s disease” |
| Pharmaceutical form | “Suspension for infusion” |
| Route of administration | “INTRACEREBRAL USE” |
| Applicant | “uniQure biopharma B.V.” |
Pharmaceutical form and concentrations in the European phase Ib/II study
| Field | Quoted record |
|---|---|
| Pharmaceutical form | “Solution for infusion” |
| Concentration, first IMP | “2 x 10e12 gc/mL” |
| Concentration, second IMP | “2 x 10e13 gc/mL” |
Dose levels administered in the phase I/II studies: vector genomes per participant
Formulation composition, fill volume, and storage conditions
No evidence found.